To study the treatment outcomes in eye disease progression in preterm babies

Outcomes of topical Ringers Lactate solution as treatment for Phase 1 Retinopathy of Prematurity - Nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/102852

Enrollment

Registered

2026-02-03

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H351- Retinopathy of prematurity

Interventions

Intervention1: Ringers Lactate eye drops: 6 times per day administered topically for a maximum of 6 months or until retinal vascularization is complete or till stages of ROP develop. If stages of ROP

Eligibility

Inclusion criteria

Inclusion criteria: Preterm neonates born between 26 to 30 weeks of gestational age

Exclusion criteria

Exclusion criteria: a)Preterm neonates with stages of Retinopathy of Prematurity b)Preterm neonates born between 26 - 30 weeks of gestational age c)Preterm neonates with any other fundus abnormality d)Systemically unstable neonates

Design outcomes

Primary

Measure	Time frame
Outcome Name - Development of retinal vascularization or stages of Retinopathy of PrematurityTimepoint: 3 months	—

Secondary

Measure	Time frame
a) Development of retinal vascularisation or stages of Retinopathy of Prematurity b) Refractive statusTimepoint: 6 months	—

Countries

India

Contacts

Public ContactDr Vignesh Elamurugan

Aravind Eye Hospital and Postgraduate Institute of Ophthalmology

vignesh.elamurugan@aravind.org914524356100

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026